Serological detection of common human melanoma membrane antigens by microcomplement fixation and immunofluorescence.

abstract：OBJECTIVE:The objective of this study was to evaluate the antitumor, survival, and adverse effects of hepatic arterial infusion chemotherapy using epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. METHODS:The study population comprised 45 consecutive patients with advanced...

journal_title：Oncology

authors： Ikeda M,Okusaka T,Ueno H,Morizane C,Iwasa S,Hagihara A,Kojima Y

更新日期：2007-01-01 00:00:00

abstract：:The association of MMP-2 (matrix metalloproteinase 2, 72-kD collagenase IV) with invasive and metastatic capacity of tumor cells has implicated a potential role in the prognosis for cancer patients. However, no larger study has been done to prove this hypothesis. The present study was therefore designed to investigate...

journal_title：Oncology

authors： Allgayer H,Babic R,Beyer BC,Grützner KU,Tarabichi A,Schildberg FW,Heiss MM

更新日期：1998-03-01 00:00:00

abstract：OBJECTIVE:Anti-p53 levels detected by different methods were compared in a predefined group of patients with breast cancer and correlated with p53 antigen expression in the corresponding tumors. METHODS:P53 autoantibodies were investigated in 165 patients with primary breast cancer using ELISAs with recombinant or nat...

journal_title：Oncology

authors： Volkmann M,Sinn HP,Gaugel D,Frey M,Hajjar Y,Ludwig J,Hänsel S,Bastert G,Wallwiener D,Fiehn W,Zentgraf H,Huober J

更新日期：2002-01-01 00:00:00

abstract：:72 patients with advanced malignant lymphoma resistant to standard chemotherapy were treated with 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) at 130 mg/m2 orally every six weeks. Objective responses were noted in 13 of 39 evaluable patients with Hodgkin's disease, three of 15 patients with lymphocytic lymphoma...

journal_title：Oncology

authors： Stolinsky DC,Solomon J,Weiner JM,Bateman JR

更新日期：1976-01-01 00:00:00

abstract：OBJECTIVES:A germline BIM deletion polymorphism has been proposed to predict a poor treatment efficacy of certain kinase inhibitors. The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). METHODS:All patients wh...

journal_title：Oncology

authors： Shao YY,Chang YL,Huang CY,Hsu CH,Cheng AL

更新日期：2013-01-01 00:00:00

abstract：:Antineoplastic properties of different Schiff bases obtained by the interaction of 5-nitrofuran with substituted pyrimidines have been examined both in vitro and in vivo. In vitro studies on L 5178Y/asparaginase sensitive, HL 60 and P 388 cell lines and in vivo studies on the P 388 cell line indicate that all the comp...

journal_title：Oncology

authors： Sur B,Chatterjee SP,Sur P,Maity T,Roychoudhury S

更新日期：1990-01-01 00:00:00

abstract：OBJECTIVE:We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian carcinoma. METHODS:Fifty-three patients were treated according to the risk of relapse: patients with stages IA or IB or with grade 1 (low risk) received 4 cycles of paclitaxel and carboplatin; pat...

journal_title：Oncology

authors： Bamias A,Bamia C,Karadimou A,Soupos N,Zagouri F,Rodolakis A,Haidopoulos D,Vlahos G,Thomakos N,Antsaklis A,Dimopoulos MA

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial. OBJECTIVE:To clarify the outcomes of recurrent and metastatic pancreatic cancers. METHODS:326 patients who received gemc...

journal_title：Oncology

authors： Hashimoto K,Ueno H,Ikeda M,Kojima Y,Hagihara A,Kondo S,Morizane C,Okusaka T

更新日期：2009-01-01 00:00:00

abstract：:5-Azacytidine (NSC-102 816) was prepared synthetically and independently isolated from the culture filtrate of Streptoverticillium ladakanus. It is an s-triazine analogue of cytidine possessing a broad spectrum of biological effects. In mammalian tissueit is phosphorylated to 5-azacytidine 5-phosphates and incorporate...

journal_title：Oncology

authors： Cihák A

更新日期：1974-01-01 00:00:00

abstract：OBJECTIVE:Transforming growth factor beta (TGF-β) plays an important role in tumorigenesis and metastasis. It works as a tumor suppressor in the normal colon, but acts as a cancer promoter during the late stages of colorectal carcinogenesis. High expression of TGF-β is known to be associated with advanced stages, tumor...

journal_title：Oncology

authors： Chun HK,Jung KU,Choi YL,Hong HK,Kim SH,Yun SH,Kim HC,Lee WY,Cho YB

更新日期：2014-01-01 00:00:00

abstract：:Objective tumor responses and survival rates with standard chemotherapy options for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) have been disappointing. However, several promising new classes of agents have emerged in recent years, including the taxanes, mitotic spindle inhibitors, antimetabol...

journal_title：Oncology

authors： Huang CH,Treat J

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:This phase I study (EudraCT No. 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors. PATIENTS AND METHODS:Patients received 2, 4, or 6 mg/kg of intr...

journal_title：Oncology

authors： Bahleda R,Baker J,Massard C,Gadgeel SM,Rogers JE,Izzedine H,Deutsch E,Garris JL,Khan A,Boelle E,Assadourian S,Soria JC,Ajani JA

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:The RUNX proteins are a family of transcriptional factors that have essential functions during embryogenesis and development, whereas deregulation in expression of RUNXs is often linked to tumor formation. To date, there has been no study describing the precise expression, prognostic impact and methylation s...

journal_title：Oncology

authors： Tonomoto Y,Tachibana M,Dhar DK,Onoda T,Hata K,Ohnuma H,Tanaka T,Nagasue N

更新日期：2007-01-01 00:00:00

abstract：:Twelve patients with advanced primary lung cancers associated with malignant pleural effusion were treated with intrathoracic instillation of recombinant interleukin-2 with or without in-vitro-sensitized cells. Two cases achieved complete response, and 7 partial response. The adverse effects seen in the protocol were ...

journal_title：Oncology

authors： Miyao H,Chou T,Ito K,Moriyama H,Mitsuma S,Wakabayashi M,Yoshizawa H,Arakawa M

更新日期：1994-01-01 00:00:00

abstract：OBJECTIVE:Syndecan-1 is a cell surface heparan sulphate proteoglycan which participates in cell proliferation, cell migration and cell-matrix interactions. Epithelial syndecan-1 expression is reduced in several malignant tumours, but in breast and pancreatic cancer, increased expression has also been described. Loss of...

journal_title：Oncology

authors： Leivonen M,Lundin J,Nordling S,von Boguslawski K,Haglund C

更新日期：2004-01-01 00:00:00

abstract：:Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treat...

journal_title：Oncology

authors： Buzdar AU,Marcus C,Holmes F,Hug V,Hortobagyi G

更新日期：1988-01-01 00:00:00

abstract：:Twenty-two patients with metastatic breast carcinoma were treated with a combination of cisplatin (100 mg/m2 i.v. day 1) and etoposide (100 mg/m2 i.v. days 1-3). Eligible patients had measurable disease with normal organ functions, performance status < 3, age < 70 years and no previous chemotherapy for metastatic dise...

journal_title：Oncology

authors： Lluch A,Azagra P,Cervantes A,Muñoz M,Alberola V,Santabarbara P,García-Conde J

更新日期：1994-07-01 00:00:00

abstract：:Adenocarcinoma of the stomach remains a significant cause of mortality worldwide. The majority of patients present with stage III or IV disease, negating surgery as a curative option. Numerous drugs have been tested over the past 2 decades in single-agent and combination chemotherapy trials. Given by intravenous bolus...

journal_title：Oncology

authors： Schnall S,Macdonald JS

更新日期：1993-04-01 00:00:00

abstract：:The expression of the drug resistance markers P glycoprotein (P-170), glutathione S transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) was analyzed in 16 human kidney carcinoma cell lines, 18 hematological malignancies, and 14 human breast carcinomas. We found a tendency for coexpression of increased P-170 and...

journal_title：Oncology

authors： Efferth T,Mattern J,Volm M

更新日期：1992-01-01 00:00:00

abstract：:Thirty-eight patients with metastatic renal-cell carcinoma (RCC) and 1 patient with a second primary RCC were treated with coumarin and cimetidine. Patients received 400 mg cimetidine p.o. daily and after 1 week 100 mg coumarin p.o. daily in addition until tumour progression. Two complete remission (30 and 50+ months)...

journal_title：Oncology

authors： Kokron O,Maca S,Gasser G,Schmidt PR

更新日期：1991-01-01 00:00:00

abstract：OBJECTIVES:It was the aim of this study to evaluate clinicopathological characteristics and prognostic factors of uterine leiomyosarcomas (LMS). METHODS:Twenty-eight patients with uterine LMS were evaluated in this retrospective study. Their features and survival were analyzed by Kaplan-Meier and log-rank tests. RESU...

journal_title：Oncology

authors： Loizzi V,Cormio G,Nestola D,Falagario M,Surgo A,Camporeale A,Putignano G,Selvaggi L

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:The phosphatidylinositol 3-kinase (PI3K) pathway plays a critical role in ovarian cancer cell survival and proliferation. The aim of this study was to determine whether the suppression of the PI3K catalytic subunit p110alphainhibits the growth of ovarian cancer cells in vitro and in vivo. METHODS:The short h...

journal_title：Oncology

authors： Zhang X,Deng HX,Zhao X,Su D,Chen XC,Chen LJ,Wei YQ,Zhong Q,Li ZY,He X,Yi T

更新日期：2009-01-01 00:00:00

abstract：:During the period 1965-1980, 84 patients with Wilms' tumor, neuroblastoma and Ewing's sarcoma were treated at the University of Rochester Medical Center. All patients were evaluated for the presence of congenital abnormalities. Ten of 34 (29%) patients with Wilms' tumor, 3 of 32 (9%) patients with neuroblastoma, and 0...

journal_title：Oncology

authors： Nakissa N,Constine LS,Rubin P,Strohl R

更新日期：1985-01-01 00:00:00

abstract：OBJECTIVE:BRAF D594G mutations in colorectal cancer patients are not clearly understood. We retrospectively investigated the clinicopathological features of colorectal cancers with BRAF D594G mutations. METHODS:We selected 908 colorectal cancer patients who underwent surgical resection from January 2008 to January 201...

journal_title：Oncology

authors： Amaki-Takao M,Yamaguchi T,Natsume S,Iijima T,Wakaume R,Takahashi K,Matsumoto H,Miyaki M

更新日期：2016-01-01 00:00:00

abstract：:A cost-effectiveness analysis is one form of full economic evaluation where drug acquisition costs and the costs that are incurred as a result of using a particular treatment are assessed together with clinical efficacy. This paper reviews two such studies. One of the studies was a prospective randomised cost-effectiv...

journal_title：Oncology

authors： Cox F,Hirsch J

更新日期：1993-05-01 00:00:00

abstract：:The priming action of estradiol and the antiestrogen tamoxifen (TMX) on progesterone receptor (PgR) synthesis has been investigated in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor model testing different priming times. Rats received either TMX or estradiol benzoate (E2B) for 3 or 7 days. Tumors were as...

journal_title：Oncology

authors： Boccardo F,Cerruti G,De Menech R,Valenti G,Zanardi S

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:There is no standard second-line therapy for patients with oesophagogastric cancer who progress following first-line chemotherapy for advanced disease or relapse following radical multi-modality therapy. The aim of this retrospective study was to evaluate survival following rechallenge with platinum plus fluoro...

journal_title：Oncology

authors： Okines AF,Asghar U,Cunningham D,Ashley S,Ashton J,Jackson K,Hawkes E,Chau I

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of ...

journal_title：Oncology

authors： Faehling M,Kopp M,Schwenk B,Fallscheer S,Kramberg S,Eckert R

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND/OBJECTIVE:Clear cell renal cell carcinoma (CCRCC) is a malignant neoplasm frequently associated with an increase in circulating immune complexes (CIC). Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) is a disease involving the chorioretinal structures of the eye, and it is commonly observe...

journal_title：Oncology

authors： Parmeggiani F,Costagliola C,D'Angelo S,Incorvaia C,Perri P,Sebastiani A

更新日期：2004-01-01 00:00:00

abstract：:Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used worldwide in cancer patients for over 1 year, and (only 5 years from the first publication on the clinical use of this growth factor) experience is rapidly accumulating in many oncological situations. Several randomized studies have confirme...

journal_title：Oncology

authors： Bronchud MH

更新日期：1994-03-01 00:00:00